Introduction
============

Parity is associated with lower lifetime breast cancer risk, with changes in differentiation of breast epithelium proposed as a protective mechanism \[[@B1]\]. However, the relationship between parity and breast cancer is complex, and it depends on age, timing of the pregnancy and tumor subtype. Despite decreased lifetime risk, parity has been suggested to increase breast cancer risk transiently following pregnancy \[[@B2]\]. Other analyses suggest a qualitative age interaction, with parity increasing risk early in life and decreasing it in older women \[[@B3]\]. The results of mechanistic studies suggest that increases in hormone levels during pregnancy or in inflammatory microenvironments present during postpartum involution \[[@B4],[@B5]\] may increase breast cancer risk in the years following a birth. However, beyond these temporal trends, there are other nuances in parity--breast cancer associations, with some data suggesting that factors such as age at first birth \[[@B2],[@B6]\], tumor estrogen receptor (ER) status \[[@B7]-[@B9]\], menopausal status or age at diagnosis \[[@B3]\] and breastfeeding patterns \[[@B10],[@B11]\] may modify these associations.

Unraveling the complexity of parity and breast cancer risk requires a better understanding of molecular changes associated with parity, together with the recognition of the heterogeneity of breast tumors. In recent studies, some researchers have described parity-induced molecular signatures based on their genome-wide expression profiling of normal breast tissues obtained from healthy women \[[@B12]-[@B14]\], which provides new insights into the molecular basis of parity-associated risk protection through alteration of transcription regulation, centrosome organization, RNA splicing, cell-cycle control, adhesion and differentiation. Meanwhile, evaluation of molecular heterogeneity of tumors has led to dramatic changes in our conceptualization of breast cancer, which is now widely recognized as representing at least five molecular subtypes with distinct clinicopathological characteristics and risk factor profiles \[[@B9],[@B15]-[@B17]\]. This tumor heterogeneity is particularly important in relation to parity because parity and early age at first full-term birth are associated with reduced risk for ER-positive (ER+) or and (ER + or PR+) breast tumors, but they do not seem to reduce, or they may even increase, lifetime risk for ER-negative (ER-), particularly triple-negative (ER - and PR - and HER2-) breast tumors \[[@B8],[@B18]-[@B23]\]. These findings suggest that parity-related factors may influence breast cancer risk through different molecular pathways in ER + and ER - tumors.

In this study, we identified a novel parity-related signature using gene expression profiling data obtained from reduction mammoplasty (RM) specimens. We then tested this parity signature, as well as signatures from previously published studies of normal tissue \[[@B12]-[@B14],[@B24]\], in paired tumor and normal tissues collected from breast cancer patients in the Polish Breast Cancer Study (PBCS) \[[@B25]\]. We demonstrate that parity-related molecular processes identified in normal breast tissues of cancer-free women were preserved in normal breast tissues from cancer patients. Furthermore, even ER + tumor tissues persisted in expressing some parity-associated gene expression patterns, suggesting that tumor biology may reflect patient exposures that predate carcinogenesis.

Methods
=======

Identification of parity-related gene expression signature
----------------------------------------------------------

### Study population and sample handling

Samples were obtained from normal breast tissue of women ages 14 to 70 years who had undergone RM surgery at Baystate Medical Center (Springfield, MA, USA) and whose tissues were banked at the Pioneer Valley Life Sciences Institute (PVLSI) between 2007 and 2010 \[[@B26],[@B27]\]. Specimens were excluded if pathologic assessment of patient-matched, paraffin-embedded tissues demonstrated benign breast disease or neoplastic lesions. Demographic and reproductive information was collected by telephone interview following surgery. The present study was limited to the subjects with complete data on parity, as well as available fresh-frozen tissues so that we could perform gene-profiling analysis, including 54 nulliparous and 76 parous women. The tissue processing, RNA isolation, microarray profiling and preprocessing of gene expression data have been described previously in detail \[[@B26],[@B27]\]. All gene expression data are publicly available through the Gene Expression Omnibus \[GSE:16113, GSE:33526\].

### Data analysis

Significance Analysis of Microarrays (SAM) was used to detect differentially expressed genes (with the nulliparous group as the reference) using false discovery rate (FDR \< 0.01) to control type I errors due to multiple testing \[[@B28]\]. This method is preferable to fold change--based thresholds methods because it accounts for both variation and multiple testing in gene selection \[[@B28]\]. Genes that were significantly differentially expressed by parity were clustered across all samples using average linkage hierarchical cluster analysis, and results were visualized using Java TreeView software \[[@B29]\]. Ontology classification and pathway analyses were performed on the identified genes using GoMiner software \[[@B30]\].

Expression of identified parity signature in tumor and paired adjacent normal tissues
-------------------------------------------------------------------------------------

### Study population and sample handling

The PBCS is a population-based case--control study conducted in two major cities in Poland (Warsaw and Łódź) from 2000 to 2003 \[[@B25]\]. The PBCS patients were women ages 20 to 74 years with newly diagnosed, pathologically confirmed *in situ* or invasive breast carcinoma identified using a rapid identification system organized at five participating hospitals and via cancer registries. Fresh tissues from invasive tumors, cancer-adjacent breast tissues and mammary fat tissues were collected from a subset of 227 patients at the time of breast surgery and snap-frozen in liquid nitrogen. Compared to other PBCS patients, the subset of 227 patients had significantly larger and node-positive tumors (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). A set of 150 paired tumor and cancer-adjacent benign breast samples, which were oversampled for basal-like and luminal cancers and associated tissues, were included in the present study. These samples were selected based on *in vitro* evidence that microenvironments associated with luminal and basal breast cancer subtypes differ \[[@B31]\]. Cancer-adjacent breast tissues used in this study were \<2 cm from the tumor edge. Information on clinicopathological, demographic and anthropometric factors was collected from medical records and in-person interviews. Procedures for construction of tumor tissue microarrays, immunohistochemical staining and scoring of key markers, including ER, have been described in detail elsewhere \[[@B32],[@B33]\].

Two-color Agilent 4 × 44K whole-genome arrays (Agilent Technologies, Santa Clara, CA, USA) were used to evaluate gene expression in cancer-adjacent normal tissues. The details regarding tissue processing, RNA isolation, microarray profiling and preprocessing of gene expression data have been described previously \[[@B34]\]. Illumina HumanRef-8 v2 Expression BeadChip arrays (Illumina, San Diego, CA, USA) were used to evaluate gene expression in tumor tissues. In brief, 250 ng of input RNA was amplified and labeled using the Illumina TotalPrep RNA amplification kit (Ambion/Life Technologies, Austin, TX, USA) according to the manufacturer's recommended protocol. The biotin-labeled cRNAs were quantitated using Quant-iT RiboGreen RNA quantitation reagent (Molecular Probes/Invitrogen, Eugene, OR, USA), and 750 ng was hybridized to Illumina HumanRef-8 v2 Expression BeadChip microarrays (Illumina). Quality checks and data normalization were conducted using standard Illumina preprocessing methods. In particular, the variance stabilization transformation was used, followed by quantile normalization. The number of significant (*P* \< 0.05) detection calls was similar across arrays. All gene expression data are publicly available through the Gene Expression Omnibus \[GSE: 49175\].

### Data analysis

We used two methods, gene set enrichment analysis (GSEA) \[[@B35]\] and Creighton correlation \[[@B36]\], to test whether the parity signatures from healthy women were associated with parity status in PBCS based on their expression values for the parity-related genes. Both parous and nulliparous women were included in these analyses. GSEA was used to test the enrichment of the parity signature identified in RM patient tissues from PVLSI (PVLSI signature) among parous compared to nulliparous PBCS women. GSEA reveals patterns of gene expression from a given gene set (RM-derived parity signature in this study), even when single-gene analysis reveals very few overlapping, statistically significant genes. A running enrichment score (ES) is calculated by walking down the entire list of probes in the PBCS gene expression array ordered by *t*-test coefficients divided by the standard error values from the parous--nulliparous comparison. This running-sum statistic increases when a given probe is in the PVLSI gene set and decreases otherwise, with the magnitude of increment depending on the strength of the correlation between the probe and the parous--nulliparous comparison in the PBCS data set. We defined the ES as the maximum deviation of the running ES from zero encountered in the random walk. It reflects the degree to which the gene set was overrepresented at the extremes of the entire ranked probe list. Distributions of ES values were created through a permutation procedure and used to calculate the statistical significance of the observed ES values. A permutation-based family-wise error rate (FWER) ≤ 15% was considered as significant. The Creighton correlation method has been described previously \[[@B34]\]. Briefly, standard vectors corresponding to all genes in the parity signature were constructed, with 1 and -1 assigned to genes with fold changes greater and smaller than the median, respectively. A Pearson correlation coefficient was calculated for this standard vector compared to the vector of median centered gene expression for each patient. Patients were classified as positive for parity signature if the Pearson correlation coefficient was greater than zero and as negative if the coefficient was less than zero. Associations of parity signatures with parity status of subjects (nulliparous versus parous) were assessed using unconditional logistic regression by estimating odds ratios (ORs) with 95% confidence intervals (CIs) and by the χ^2^ test (or Fisher's exact test when expected cell count was less than five) for *P*-values with a threshold for significance equal to 0.05.

The GSEA and Creighton methods are analytically and conceptually different and were used to test two related but distinct questions. We used GSEA to test whether there was a significant subgroup of the genes in the parity signature that was differentially expressed in parous versus nulliparous cancer patients. The Creighton method was used to test whether the parity signature as a whole could predict parity status of cancer patients. Sensitivity analyses were performed to assess heterogeneity of gene expression among cancer patients. GSEAs were stratified by age at first birth (≤ 25 years versus \> 25 years prior), interval since most recent birth (\< 10 years versus ≥ 10 years) and menopausal status.

Comparison with previously published parity signatures
------------------------------------------------------

We assessed two previously published data sets designed to identify gene expression signatures by parity in normal human tissues: (1) a candidate gene study by Asztalos *et al.*\[[@B24]\], who examined the expression of 64 candidate genes using real-time PCR in mammoplasty benign biopsy specimens from 13 nulliparous and 11 parous age-matched premenopausal women from the University of Illinois at Chicago Hospital (UICH); and (2) a genome-wide expression data set (GeneChip Human Genome U133 Plus 2.0 oligonucleotide array; Affymetrix, Santa Clara, CA, USA) based on normal breast samples from 67 parous and 40 nonparous postmenopausal healthy volunteers recruited at the Sunderby Hospital in Luleå, Sweden (SHL). The SHL expression profiling data set was published in three independent papers (Belitskaya-Lévy *et al.*\[[@B12]\], Russo *et al.*\[[@B13]\] and Peri *et al.*\[[@B14]\]). Because these three research groups used similar statistical methods and generated similar parity signatures, we focused our comparisons on the signature published first, in the paper by Belitskaya-Lévy *et al*. Parity-related genes from the two signatures (UICH and SHL) are listed in Additional file [1](#S1){ref-type="supplementary-material"}: Table S2. The associations between parity and gene expression of UICH and SHL parity signatures were evaluated in normal tissues from the PVLSI study and in tumor and paired cancer-adjacent normal tissues from the PBCS, using the Creighton correlation and GSEA as described above. Data analyses were performed using R (version 3.0.0) \[[@B37]\].

The study protocols were approved by the institutional review boards (IRBs) of each participating institution, and written informed consent was obtained from every participant. The IRB at Baystate Medical Center approved RM sample procurement for the PVLSI women, and the IRB at the University of North Carolina approved the microarrays and statistical analyses of these samples. For the PBCS cases, the collection of breast tissues, questionnaire data and consent for the analyses presented here were covered by the protocol of the Breast, Ovarian and Endometrial Cancer Case--Control Study in Poland, which was approved by the National Cancer Institute Special Studies IRB (OH99CN040).

Results
=======

Comparison of sample sets
-------------------------

There were some differences in subject characteristics, source of breast tissues and expression profiling platforms across different studies (Table [1](#T1){ref-type="table"}). Although the fresh whole-breast tissue analyzed in PVLSI RMs, PBCS cancer-adjacent normal tissues and SHL core biopsies consisted of both stromal and epithelial tissues, epithelial cells were microdissected in the UICH sample and comprised the dominant cell type in tumors from the PBCS. As is typical for women undergoing RM, PVLSI and UICH patients tended to be more obese and younger (therefore premenopausal) than the SHL and PBCS patients. The PVLSI patients were also younger (mean age = 37 years) and more likely to have had a most recent birth \< 10 years prior (68%) than were breast cancer patients in the PBCS group (3%).

###### 

**Differences in study design, experimental approaches and sample characteristics**^**a**^

  **Study demographics**     **PVLSI**            **SHL**^**b**^\[[@B12]\]   **UICH**^**b**^\[[@B24]\]    **PBCS cancer-adjacent normal tissue**   **PBCS tumor tissue**
  -------------------------- -------------------- -------------------------- ---------------------------- ---------------------------------------- -----------------------
  Cancer status              Cancer-free          Cancer-free                Cancer-free                  Breast cancer                            Breast cancer
  Tissue source              Fresh whole tissue   Core needle biopsies       Microdissected FFPE tissue   Fresh whole tissue                       Fresh whole tissue
  Tissue enrichment          Stroma               Epithelial and stromal     Epithelial                   Stroma                                   Epithelial
  Gene expression platform   Agilent 4 × 44K      GeneChip U133Plus 2.0      RT-PCR of 64 genes           Agilent 4 × 44K                          Illumina
  Samples                                                                                                                                          
    Total                    130                  107                        24                           150                                      
    ER+, *n* (%)             N/A                  N/A                        N/A                          117 (78%)                                
    Parous, *n* (%)          76 (58%)             67 (63%)                   11 (46%)                     119 (79%)                                
    Premenopausal, *n* (%)   84 (65%)             0 (0%)                     24 (100%)                    41 (27%)                                 
  Mean age (±SD), yr         37 (13)              60 (5)                     29 (6)                       56 (10)                                  
  Mean BMI (±SD)             30^c^ (6)            25 (4)                     --                           28 (5)                                   

^a^%, Percentage for categorical variables; BMI, Body mass index; FFPE, Formalin-fixed, paraffin-embedded; N/A, Not applicable; PBCS, Polish Breast Cancer Case--Control Study; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; SD, Standard deviation for continuous variables; SHL, Normal breast samples from 107 postmenopausal healthy volunteers recruited at the Sunderby Hospital in Luleå, Sweden; UICH, Mammoplasty benign biopsy specimens from 24 premenopausal women from the University of Illinois at Chicago Hospital. ^b^From previously published, parity-related gene expression signatures in healthy women \[[@B12],[@B24]\]. ^c^There were 56 (43%) missing BMI values in the PVLSI group.

Discovery of parity signature in PVLSI mammoplasty specimens
------------------------------------------------------------

By gene expression profiling analysis of PVLSI samples, we identified 251 upregulated genes (and no downregulated genes) associated with parity (with nulliparous women used as a reference; FDR = 0.008). Gene names, fold changes, FDRs and *P*-values are listed in Additional file [1](#S1){ref-type="supplementary-material"}: Table S3. The prediction of parity status based on the clustering with this parity signature (Figure [1](#F1){ref-type="fig"}) showed fair agreement with actual phenotype, with greater accuracy seen among parous women (accuracy = 76%) than in nulliparous women (accuracy = 54%). We examined whether the parity-associated gene expression signature varied by age at first birth (≤ 25 years versus \> 25 years), interval between most recent birth and tissue collection (\< 10 versus ≥ 10 years) and menopausal status in the RM data set. The predictive accuracy of the identified parity signature among parous women did not differ significantly by age at first birth (70% for ≤ 25 years versus 57% for \> 25 years; *P* = 0.28), interval since most recent birth (60% for \<10 years versus 75% for ≥ 10 years; *P* = 0.19) or menopausal status (62% for premenopausal versus 61% for postmenopausal women; *P* = 0.92).

![**Unsupervised HeatMap cluster analysis.** The heatmap illustrates our analysis of the 251 parity-related gene expression profiles of normal breast samples from cancer-free women who had undergone reduction mammoplasty surgery at Baystate Medical Center (Springfield, MA, USA) and whose tissue is banked at the Pioneer Valley Life Sciences Institute.](bcr3689-1){#F1}

Pathway analysis suggested that significant genes were associated with immune, inflammation and wound responses. The top ten significant Gene Ontology database biological processes are shown in Table [2](#T2){ref-type="table"}. A complete list is available in Additional file [1](#S1){ref-type="supplementary-material"}: Table S4.

###### 

**Top ten Gene Ontology database biological processes enriched by the 251 genes significantly upregulated in normal breast samples of parous compared to nulliparous cancer-free PVLSI patients**^**a**^

  **GO category**                                       **Gene names**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Total**   **Up**   ***P*-value**   **FDR**
  ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- -------- --------------- ----------
  \[GO: 0002376\] Immune system process                 KLHL6, HCLS1, LAT2, CD93, SLC7A7, DOK2, NCF4, PTPRC, VNN1, CD38, MAFB, CCL2, ITK, ATP6V0A2, HCK, BLNK, TBX21, FCGR2B, FYB, BPGM, SCIN, CLEC4A, CD244, CD247, TFEB, SNCA, CD48, TNFSF13B, IL6R, TLR3, CDKN2A, P2RX7, SYK, LCP1, C3AR1, ENPP3, ANXA3, VAV1, LCP2, NDFIP1, CD14, TLR1, CD83, CSF1, TLR7, ITGAM, BST1, HLA-DMA, CYBB, EPB42, PRG4, NCF1, WAS, SIX1, TLR6, CCR1, IL1R2, EDA, ITGB2, NCF2, CD28, CCL3                                                                                                                                                                                                                                                1,040       62        5.3E-19      \< 0.001
  \[GO: 0006955\] Immune response                       KLHL6, ENPP3, ANXA3, LAT2, LCP2, NDFIP1, NCF4, PTPRC, CD14, VNN1, CD38, TLR1, CD83, CCL2, TLR7, ITK, ATP6V0A2, BLNK, TBX21, FCGR2B, FYB, BST1, CLEC4A, HLA-DMA, CYBB, PRG4, CD247, NCF1, TFEB, SNCA, WAS, TNFSF13B, IL6R, TLR3, TLR6, CCR1, IL1R2, EDA, ITGB2, SYK, P2RX7, NCF2, LCP1, CD28, CCL3, C3AR1                                                                                                                                                                                                                                                                                                                                                        611        46        8.9E-18      \< 0.001
  \[GO: 0006952\] Defense response                      RNASE6, ANXA3, ADORA3, C1ORF38, ESR2, NDFIP1, PTPRC, CD14, VNN1, NLRC4, TLR1, CD83, CCL2, TLR7, ITK, HCK, BLNK, NOX4, HRH1, CLEC4A, CYBB, CD247, NCF1, SNCA, WAS, CD48, IL6R, LILRB3, TLR3, ALOX5AP, TLR6, AIF1, CCR1, ITGB2, P2RX7, LILRA3, NCF2, CD28, CCL3, C3AR1                                                                                                                                                                                                                                                                                                                                                                                            578        40        3.1E-14      \< 0.001
  \[GO: 0045321\] Leukocyte activation                  ANXA3, VAV1, LAT2, CD93, LCP2, NDFIP1, PTPRC, VNN1, TLR1, CD38, CD83, CSF1, TLR7, BLNK, ITGAM, TBX21, HLA-DMA, CD247, SNCA, WAS, CD48, TNFSF13B, TLR3, CDKN2A, TLR6, P2RX7, SYK, LCP1, CD28                                                                                                                                                                                                                                                                                                                                                                                                                                                                     336        29        7.5E-13      \< 0.001
  \[GO: 0006954\] Inflammatory response                 CYBB, ADORA3, C1ORF38, NDFIP1, CD14, IL6R, VNN1, NLRC4, TLR1, TLR3, ALOX5AP, CCL2, TLR7, AIF1, TLR6, CCR1, ITGB2, BLNK, P2RX7, NOX4, HRH1, C3AR1, CCL3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          265        23        1.9E-10      \< 0.001
  \[GO: 0002682\] Regulation of immune system process   KLHL6, VAV1, LAT2, LCP2, NDFIP1, PTPRC, VNN1, CD38, CD83, MAFB, CSF1, TLR7, ITK, HCK, TBX21, FCGR2B, FYB, SCIN, HLA-DMA, CD247, SNCA, TNFSF13B, WAS, IL6R, TLR3, CDKN2A, TLR6, ITGB2, SYK, P2RX7, CD28, C3AR1                                                                                                                                                                                                                                                                                                                                                                                                                                                   513        32        2.5E-10      \< 0.001
  \[GO: 0002274\] Myeloid leukocyte activation          TLR1, TLR3, ANXA3, CSF1, LAT2, CD93, TLR7, TLR6, LCP2, SYK, SNCA, CD48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          63         12        6.9E-10      \< 0.001
  \[GO: 0009611\] Response to wounding                  VAV1, IL10RA, SLC7A7, ADORA3, C1ORF38, LCP2, DOK2, NDFIP1, CD14, GATM, VNN1, TLR1, NLRC4, CCL2, TLR7, BLNK, ITGAM, NOX4, HRH1, CYBB, CD244, WAS, CD48, IL6R, TLR3, ALOX5AP, TLR6, AIF1, CCR1, ITGB2, SYK, P2RX7, LAMP2, PIK3CG, CCL3, C3AR1                                                                                                                                                                                                                                                                                                                                                                                                                     671        36        1.1E-09      \< 0.001
  \[GO: 0001775\] Cell activation                       ANXA3, VAV1, LAT2, CD93, LCP2, NDFIP1, PTPRC, VNN1, CD38, TLR1, CD83, CSF1, TLR7, BLNK, ITGAM, TBX21, HLA-DMA, CD247, SNCA, WAS, CD48, TNFSF13B, TLR3, CDKN2A, TLR6, P2RX7, SYK, LAMP2, LCP1, CD28, PIK3CG                                                                                                                                                                                                                                                                                                                                                                                                                                                      520        31        1.5E-09      \< 0.001
  \[GO: 0050896\] Response to stimulus                  HCLS1, KLHL6, FPR3, ANG, LAT2, IL10RA, SLC7A7, CACNA2D4, C1ORF38, PTGIS, DOK2, NCF4, PTPRC, VNN1, PTPRO, CD38, NLRC4, FGF1, CCL2, ITK, ATP6V0A2, HCK, PTGS1, BLNK, TBX21, NOX4, HRH1, FCGR2B, FYB, CLEC4A, HTR2B, CD244, CD247, TFEB, SNCA, TNFSF13B, CD48, IL6R, LILRB3, TLR3, ALOX5AP, CDKN2A, AIF1, SYK, P2RX7, LILRA3, LCP1, CRY1, LAMP2, C3AR1, ENPP3, ANXA3, RNASE6, VAV1, ADORA3, LCP2, ESR2, NDFIP1, CD14, GATM, DYNLRB1, TLR1, CD83, TBXAS1, KCNQ1, CYP4V2, C20ORF39, HSPA6, TLR7, CYB5R4, MAOB, ITGAM, ATP6V1F, BST1, HLA-DMA, CYBB, PRG4, NCF1, WAS, ABLIM2, GDF10, TLR6, CCR1, CNGA1, AGPS, IL1R2, EDA, ITGB2, NCF2, CD28, TFEC, PIK3CG, CCL3      3,121       93        2.0E-09      \< 0.001

^a^FDR, False discovery rate; GO, Gene Ontology; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; Up, Upregulated.

Assessment of three parity signatures in mammoplasty samples, cancer-adjacent tissues and cancer tissues
--------------------------------------------------------------------------------------------------------

We assessed the enrichment of the three parity signatures (PVLSI, SHL and UICH) in three different tissue sample sets: (1) mammoplasty tissues from PVLSI; (2) cancer-adjacent, histologically normal tissue from PBCS participants with invasive breast cancer; and (3) paired tumor tissues from the same PBCS women. The results of this analysis are shown in Table [3](#T3){ref-type="table"}.

###### 

**Associations between parity in PVLSI and PBCS data sets and gene expression enrichment**^**a**^

                                         **PVLSI signature**    **SHL signature**    **UICH signature**                         
  ------------------------------------- --------------------- --------------------- --------------------- ---------- ---------- ----------
  PVLSI normal tissues                                                                                                          
    GSEA ES^b^                                  0.98                  -0.52                 0.71                                
    GSEA FWER^b^                              0% (sig)                 N/A                3% (sig)                              
    Creighton analysis^c^                     Negative              Positive              Negative         Positive   Negative   Positive
    Nulliparous                               37 (69%)              17 (31%)              22 (41%)         32 (59%)   33 (61%)   21 (39%)
    Parous                                    27 (36%)              49 (64%)              45 (59%)         31 (41%)   30 (39%)   46 (61%)
    OR (95% CI)^d^                       3.95 (1.88 to 8.29)   0.47 (0.23 to 0.96)   2.4 (1.18 to 4.92)                         
    *P*-value^e^                            0.0002 (sig)               N/A               0.015 (sig)                            
  PBCS cancer-adjacent normal tissues                                                                                           
    GSEA ES^b^                                  0.52                  0.24                  0.60                                
    GSEA FWER^b^                              5% (sig)                 37%                14% (sig)                             
    Creighton analysis^c^                     Negative              Positive              Negative         Positive   Negative   Positive
    Nulliparous                               17 (57%)              13 (43%)              16 (53%)         14 (47%)   15 (50%)   15 (50%)
    Parous                                    58 (49%)              61 (51%)              62 (52%)         57 (48%)   62 (52%)   57 (48%)
    OR (95% CI)^d^                       1.38 (0.61 to 3.08)   1.05 (0.47 to 2.34)   0.92 (0.41 to 2.05)                        
    *P*-value^e^                                0.44                  0.90                  0.84                                
  PBCS tumor tissues                                                                                                            
    GSEA ES^b^                                  0.47                  0.40                  0.58                                
    GSEA FWER^b^                                 18%                   24%                   21%                                
    Creighton analysis^c^                     Negative              Positive              Negative         Positive   Negative   Positive
    Nulliparous                               16 (53%)              14 (47%)              14 (47%)         16 (53%)   21 (70%)   9 (30%)
    Parous                                    58 (49%)              61 (51%)              55 (46%)         64 (54%)   65 (55%)   54 (45%)
    OR (95% CI)^d^                       1.20 (0.54 to 2.68)   1.02 (0.56 to 2.27)   1.94 (0.82 to 4.58)                        
    *P*-value^e^                                0.65                  0.96                  0.13                                

^a^CI, Confidence interval; ES, Enrichment score; FDR, False discovery rate; FWER, Family-wise error rate; GSEA, Gene set enrichment analysis; OR, Odds ratio; N/A, Not applicable; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; SHL, Normal breast samples from 107 postmenopausal healthy volunteers recruited at the Sunderby Hospital in Luleå, Sweden; UICH, Mammoplasty benign biopsy specimens from 24 premenopausal women from the University of Illinois at Chicago Hospital. ^b^In GSEA analysis, ES indicates the GSEA enrichment score and FWER is the corresponding family-wise error rate and considered significant (sig) if ≤ 15%. ^c^In Creighton analysis, "Positive" and "Negative" indicate enriched and not enriched expression of parity signature, respectively. ^d^In Creighton analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by unconditional logistic regression analysis with observed parity as the outcome variable and nulliparity as the reference. ^e^In Creighton analysis, *P*-values were obtained by χ^2^ test or Fisher's exact test if the expected cell count was less than five, and considered significant (sig) if ≤ 0.05.

Gene expression of the identified PVLSI parity signature was strongly enriched by parity in its PVLSI training set as expected (ES~GSEA~ = 0.98, FWER~GSEA~ = 0%, OR~Creighton~ = 3.95, *P*-value~Creighton~ = 0.0002). Considering all invasive cancer patients (ER + and ER - cases combined), GSEA analyses showed that, though enrichment was weaker than among normal RM tissues, there was a significant enrichment of the PVLSI parity signature in tumor-adjacent normal tissues (ES~GSEA~ = 0.52, FWER~GSEA~ = 5%). The parity signature was further diluted and was then no longer significant in tumor tissues (ES~GSEA~ = 0.47, FWER~GSEA~ = 18%). The results obtained using the Creighton correlation method were consistent with those based on GSEA.

The UICH signature reported by Asztalos *et al*. \[[@B24]\] was significantly positively correlated with parity in normal PVLSI tissues on the basis of both GSEA and Creighton analysis (ES~GSEA~ = 0.71, FWER~GSEA~ = 3%, OR~Creighton~ = 2.4, *P*-value~Creighton~ = 0.01). Similar to our PVLSI signature, the UICH signature also showed a gradient loss of enrichment from normal samples to tumor samples on the basis of GSEA results, but not in the Creighton analysis, which is based on a dichotomous classification.

We did not observe any significant positive association or trend between the SHL signature and parity in the three examined tissue data sets.

Evaluation of parity signatures in benign cancer adjacent and cancer tissues by estrogen receptor status
--------------------------------------------------------------------------------------------------------

To study the distinct effect of parity by breast cancer subtype, we evaluated the enrichment of parity signatures when PBCS samples were stratified by tumor ER status. As shown in Table [4](#T4){ref-type="table"}, by GSEA, we observed that our PVLSI signature was significantly enriched by parity in ER + patients (cancer-adjacent normal: ES~GSEA~ = 0.45, FWER~GSEA~ = 12%; tumor: ES~GSEA~ = 0.50, FWER~GSEA~ = 15%), but not among ER - patients (cancer-adjacent normal: ES~GSEA~ = 0.37, FWER~GSEA~ = 21%; tumor: ES~GSEA~ = 0.31, FWER~GSEA~ = 44%). Consistently, the results of the Creighton analysis showed opposite associations of parity with our PVLSI parity signature by tumor ER status in both cancer-adjacent normal tissues (ER+: OR~Creighton~ = 1.53; ER-: OR~Creighton~ = 0.44) and tumor tissues (ER+: OR~Creighton~ = 1.91; ER-: OR~Creighton~ = 0.83), although these associations were not statistically significant. Overall, these trends suggest that the parity signature remains weakly expressed in the tissues of ER + breast cancer patients.

###### 

**Associations between parity and gene expression enrichment of PVLSI parity signature in cancer-adjacent and tumor tissues from PBCS patients by estrogen receptor tumor type**^**a**^

                           **Cancer-adjacent normal tissue, ER+**   **Tumor tissue, ER+**   **Cancer-adjacent normal tissue, ER-**   **Tumor tissue, ER-**                                   
  ----------------------- ---------------------------------------- ----------------------- ---------------------------------------- ----------------------- ---------- ---------- ---------- ----------
  GSEA ES^b^                                0.45                            0.50                             0.37                            0.31                                            
  GSEA FWER^b^                           12% (sig)                        15% (sig)                          21%                              44%                                            
  Creighton analysis^c^                   Negative                        Positive                         Negative                        Positive          Negative   Positive   Negative   Positive
    Nulliparous                           16 (62%)                        10 (38%)                         15 (58%)                        11 (42%)          1 (25%)    3 (75%)    1 (25%)    3 (75%)
    Parous                                46 (51%)                        44 (49%)                         50 (56%)                        40 (44%)          12 (43%)   16 (57%)   8 (29%)    20 (71%)
    OR (95% CI)^d^                  1.53 (0.63 to 3.73)              1.91 (0.45 to 2.6)              0.44 (0.04 to 4.82)              0.83 (0.07 to 9.25)                                    
    *P*-value^e^                            0.35                            0.85                             0.63                            1.00                                            

^a^CI, 95% confidence interval; ER, Estrogen receptor; ES, Enrichment score; FWER, Family-wise error rate; GSEA, Gene set enrichment analysis; OR, Odds ratio; PBCS, Polish Breast Cancer Case--Control Study; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; sig, Significant. ^b^In GSEA analysis, ES indicates the GSEA enrichment score and FWER the corresponding family-wise error rate, with results considered significant (sig) if ≤ 15%. ^c^In Creighton analysis, "Positive" and "Negative" indicate enriched and nonenriched expression of parity signature. ^d^In Creighton analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by unconditional logistic regression analysis with observed parity as the outcome variable and nulliparity as the reference. ^e^In Creighton analysis, *P*-values were obtained by χ^2^ test or Fisher's exact test if the expected cell count was less than five, and values were considered significant (sig) if ≤ 0.05.

We also observed differences in parity associations by ER status for SHL and UICH signatures (data not shown); however, these associations were weaker than those for the PVLSI signature.

We refined the parity signature by identifying 41 genes consistently associated with parity across all three GSEA analyses and significantly enriched for PVLSI signature by parity status, that is, in cancer-adjacent normal tissue overall and in ER + as well as ER + tumor tissue analyses (see Table [5](#T5){ref-type="table"} and top 41 genes in Additional file [1](#S1){ref-type="supplementary-material"}: Table S3). A pathway analysis based on these 41 genes revealed the following top 10 biological processes: response to wounding; leukocyte, cell, lymphocyte and T-cell activation; immune system process; cellular response to calcium ion; and immune, inflammatory and defense responses.

###### 

**Forty-one genes associated with parity across all three gene set enrichment analyses**^**a**^

  **Gene symbol**   **Gene name**                                                **FC**^**b**^   ***P*-value**^**b**^   **FDR**^**b**^
  ----------------- ----------------------------------------------------------- --------------- ---------------------- ----------------
  CD163L1           Scavenger receptor cysteine-rich type 1 protein M160             1.50              0.00006                0
  FCGR2A            Fc fragment of IgG, low affinity IIa, receptor for (CD32)        1.61              0.00006                0
  ALOX5AP           Arachidonate 5-lipoxygenase-activating protein                   1.52              0.00007                0
  VNN1              Vanin 1                                                          1.62              0.00007                0
  CD33              CD33 antigen (gp67)                                              1.54              0.00007                0
  CD28              CD28 antigen (Tp44)                                              1.84              0.00007                0
  FCGR2B            Fc fragment of IgG, low-affinity IIb, receptor for (CD32)        1.92              0.00009                0
  EAF2              ELL-associated factor 2                                          1.27              0.00009                0
  LCP2              Lymphocyte cytosolic protein 2                                   1.25              0.00011                0
  IL10RA            Interleukin 10 receptor, α                                       1.32              0.00011                0
  BLNK              B-cell linker                                                    1.34              0.00012                0
  SAMSN1            SAM domain, SH3 domain and nuclear localization, 1               1.43              0.00013                0
  CYB5R4            NADPH cytochrome B5 oxidoreductase                               1.33              0.00017                0
  HTR2B             5-hydroxytryptamine (serotonin) receptor 2B                      1.69              0.00031                0
  TTC7A             Tetratricopeptide repeat domain 7A                               1.17              0.00032                0
  ATP6V1F           ATPase, H + transporting, lysosomal 14 kDa, V1 subunit F         1.20              0.00034                0
  TLR7              Toll-like receptor 7                                             1.28              0.00037                0
  ANKRD27           Ankyrin repeat domain 27 (VPS9 domain)                           1.19              0.00041                0
  ITGAM             Integrin, α M                                                    1.55              0.00044                0
  CCDC109B          Hypothetical protein FLJ20647                                    1.27              0.00045                0
  CPVL              Carboxypeptidase, vitellogenic-like                              1.48              0.00048                0
  LEPROTL1          Leptin receptor overlapping transcript-like 1                    1.19              0.00062              0.003
  CCR1              Chemokine (C-C motif) receptor 1                                 1.30              0.00068              0.004
  S100A10           S100 calcium binding protein A10                                 1.45              0.00073              0.004
  ALG14             Hypothetical protein MGC19780                                    1.26              0.00093              0.004
  SLC7A7            Solute carrier family 7, member 7                                1.30              0.00093              0.004
  CHRDL1            Chordin-like 1                                                   1.52              0.00095              0.004
  S100A4            S100 calcium binding protein A4                                  1.40              0.00098              0.004
  ITGAE             Integrin α E                                                     1.27              0.00098              0.004
  CCL2              Chemokine (C-C motif) ligand 2                                   1.51              0.00102              0.004
  CYP4X1            Cytochrome P450, family 4, subfamily X, polypeptide 1            1.49              0.00128              0.004
  CCNDBP1           Cyclin D-type binding-protein 1                                  1.18              0.00144              0.006
  TNFSF13B          Tumor necrosis factor (ligand) superfamily, member 13b           1.30              0.00148              0.006
  BLVRA             Biliverdin reductase A                                           1.24              0.00163              0.006
  C8orf40           Hypothetical protein BC013035                                    1.15              0.00174              0.006
  BIN2              Bridging integrator 2                                            1.20              0.00185              0.006
  CD48              CD48 antigen (B-cell membrane protein)                           1.26              0.00188              0.006
  TSG101            Tumor susceptibility gene 101                                    1.13              0.00199              0.006
  GLRX              Glutaredoxin (thioltransferase)                                  1.40              0.00200              0.006
  B3GALT4           β 1,3-galactosyltransferase, polypeptide 4                       1.25              0.00206              0.006

^a^FC, Fold change; FDR, False discovery rate; IgG, Immunoglobulin G; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; SAM, Sterile α domain. ^b^Fold change (FC), *P*-value and false discovery rate (FDR) are derived from gene expression comparison of cancer-free parous versus nulliparous PVLSI women. Genes shown were significantly enriched for PVLSI signature by parity status, that is, in analyses of cancer-adjacent normal tissue overall and estrogen receptor--positive and estrogen receptor--positive tumor tissues.

Discussion
==========

In this study, we identified a significant gene expression signature that was upregulated in breast tissues of parous compared to nulliparous healthy women. Similar to a previously published parity-related signature by Asztalos *et al.*\[[@B24]\] (UICH), which was constructed by selecting genes from the literature, our newly identified signature (selected using an agnostic, supervised analysis) was enriched for inflammation and immune response genes. Although researchers have previously shown in animal studies that upregulation of inflammatory response--related genes was present in the early days of involution and diminished as involution progressed \[[@B38]-[@B40]\], our findings suggest that pregnancy has a lasting effect that can be detected many years after completion of a pregnancy. In contrast, the SHL study investigators did not show an increase in immune activity in postmenopausal women and concluded that the upregulation of inflammation and immune response--related genes persists during postpartum involution but wanes after menopause \[[@B12]\]. However, the subjects in the SHL study were much older (mean age = 60 years) than the PVLSI and UICH patients (mean ages = 37 and 29 years, respectively).

We tested three parity-related signatures in genome-wide expression profiling data sets derived from paired tumor-adjacent normal and breast tumor tissues collected from breast cancer cases. We found that parity-related gene signatures were preserved in adjacent normal and tumor tissues, but only among patients with ER + tumors. This is interesting in light of our recent findings suggestive of immune response signatures being dysregulated in normal tissue adjacent to triple-negative breast cancers (P Casbas-Hernandez *et al.*, unpublished data). It is possible that some of the inflammatory genes altered by parity are also responsive to the development of ER - breast cancer and, therefore, that parity-associated signatures become disrupted with progression of ER - disease. The results of our previous work suggest that cancer-adjacent microenvironments show altered expression of wound response genes \[[@B27]\]. ER-, and especially triple-negative, breast cancers may be particularly prone to upregulated cytokines or inflammatory responses, which may lead to the disruption of the parity-associated proinflammatory pathways in ER - breast cancers. However, it is important to note that cytokines that are traditionally associated with inflammation may also play a regulatory role in breast tissue without inducing an immune response \[[@B41]\]. In the absence of direct evidence of inflammatory infiltrates, the inflammation signatures must be interpreted as a change in microenvironment without specifying particular immune suppression or immune avoidance mechanisms. Alternatively, differential expression of parity-associated signatures in ER + versus ER - disease may reflect the differential effect of parity on ER + versus ER - tumors. It appears that, in any case, pregnancy is associated with persistent changes in gene expression that are preserved in women with ER + breast cancer. In a recent study, researchers found that parity decreased the number of hormone receptor--positive luminal cells but had no effect on the basal stem and/or progenitor cells \[[@B42]\]. This suggests that parity may act differently on cells that become luminal versus basal-like breast cancers. If the parity signature is expressed predominantly in normal breast luminal epithelium, then it may be expected that the signature will be expressed only in luminal tumors. Alternatively, the proinflammatory signaling that has been associated with a basal-like stromal response \[[@B43]\] may obscure or disrupt the cytokine expression induced by parity. Identifying the differential effects of parity on distinct cell populations and showing their relevance in human tissues is important for identifying targetable pathways in cancer prevention.

The variations we observed in the expression of the parity signature by ER status are unlikely to have been driven by age, age at first birth or years since most recent birth, because these variables had similar distributions in the ER + and ER - cases evaluated. In addition, the RM-derived parity signature was not significantly associated with tumor characteristics (tumor size, histology, differentiation or lymph node positivity), nor was it associated with overall survival in Kaplan-Meier analyses (data not shown). These data suggest that the signature reflects parity status in ER + breast cancer cases and not a tendency for parous women to have a different prevalence of a particular subtype of breast cancer. However, the weaker association between the gene signature and parity in tumors (relative to normal) is suggestive of the fact that, as tumors progress, they devolve to more unstable states which no longer accurately reflect exposure history.

Comparison of signatures across data sets is challenging because of the differences in profiling platforms, methods of gene selection, patient characteristics (for example, age and body mass index (BMI)) and sample procurement procedures in different studies. Consistent with this, we found limited concordance in parity-related gene content results across different signatures. Some of the previously published signatures \[[@B12]\] were obtained primarily in microdissected epithelium, whereas our novel signature was obtained from the analysis of RM breast tissues that consisted of both epithelium and stroma. The discrepancies in gene signatures emphasize the challenges of obtaining a consistent parity signature with tissues that differ in composition. Our findings add new knowledge about how such signatures persist across the diversity of cell types in breast tissue, an understudied field. Stromal cells predominate in noninvolved, tumor-adjacent tissues, and stromal responses are important to understanding the selective pressures faced by tumors evolving from surrounding stroma \[[@B44]-[@B47]\].

In spite of these differences, several signatures showed consistent associations across data sets. Further, some genes were common across signatures. *ESR2* was identified as one of the top significantly upregulated genes in parous women in both the PVLSI and UICH studies. *ESR2* is an ER isoform that has been shown to oppose the proliferative effect of *ESR1*\[[@B48]\]. Increased expression of *ESR2* following pregnancy may reduce the proliferation of breast epithelial cells. Interestingly, in the SHL study, the researchers identified other genes in the ER signaling pathway that were upregulated in parous women, such as *GATA3*. GATA3 is a transcription factor that regulates luminal epithelial cell differentiation in the mammary gland and whose expression is highly associated with ER. Together with the finding of *ESR2* upregulation in the PVLSI and UICH studies, these data suggest that genes involved in the ER-regulated pathways could be under permanent transcriptional modification as a manifestation of a higher degree of parity-associated cell differentiation. In addition, consistent with the SHL study, our parity signature also consisted of upregulated genes. One gene in common between the SHL and PVLSI signatures was TRAF3-interacting, c-Jun N-terminal kinase--activating modulator (*TRAF3IP3*). Genes involved in cell adhesion and differentiation of leukocytes were found to be enriched in both signatures.

Overall, the separation of gene expression by parity status in our data derived from RM patients was not as strong as for other risk factors such as obesity \[[@B26]\], with expression of the signature not found to be in the expected direction in some parous women. This may suggest heterogeneity among patients or the effects of parity on the breast microenvironment being transient. However, other recent findings suggest that parity may alter the composition of breast tissue, notably shifting the tissue composition toward greater adiposity, and these effects may be persistent (X Sun *et al.*, unpublished data). Thus, the persistent inflammatory effects observed in our data may reflect a smoldering inflammatory reaction or a long-lasting shift in stromal composition rather than an acute reaction observed during postlactation involution \[[@B5],[@B49]\]. We cannot exclude some confounding by BMI or age in these analyses, because (1) BMI information was available for only half of the RM patients and (2) most parous women in this data set were also older. Nevertheless, the BMI distributions (mean ± standard deviation (SD)) in parous women (mean = 31, SD = 6) and nulliparous women (mean = 30, SD = 6) were very similar. In addition, BMI is only modestly increased with parity \[[@B50]\], and more substantial changes with BMI are associated with age \[[@B51]\]. We verified that the large majority of the identified parity genes were not part of the age- or BMI-related signature identified in the same population \[[@B26],[@B52]\]. Other variables, such as age at first birth and years since most recent birth, may affect gene expression patterns. However, our present study is not powered to address these questions. None of the subgroup analyses we conducted yielded significant results (FWER \> 15%), but future studies addressing these relationships and adequately powered for subanalyses of how plausible confounders (including age, BMI, lactation, number of children, age at first birth and years since most recent birth) influence gene expression--parity associations will be helpful.

Conclusions
===========

The strength of our study includes the identification of a novel, parity-related signature in stroma-rich breast tissue from healthy women and comparisons with different parity signatures. We tested multiple signatures in both cancer-adjacent and tumor tissues in the same set of breast cancer patients derived from a population-based study to assess whether parity-related signatures were related to tumor progression and subtype heterogeneity. However, our study also has limitations. The small sample size in the training (PVLSI) and test (PBCS) sets prohibited analyses matching on important confounders such as age and BMI or on finer subtypes such as triple-negative or basal-like tumors. In addition, the variation in study subjects, tissues and methods across studies posed challenges to reproducing parity signatures across data sets. Despite these limitations, we found that inflammatory and immune responses and ER regulatory pathways were commonly associated with parity in multiple data sets. Furthermore, parity-related molecular changes appeared to be preserved in breast cancer patients with ER + tumors but disrupted in patients with ER - tumors, which may at least partially account for the observed differential effect that parity has on these two tumor subtypes.
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